Study of FLT3 Signaling in Leukemia
Author Information
Author(s): Gu Ting-lei, Nardone Julie, Wang Yi, Loriaux Marc, Villén Judit, Beausoleil Sean, Tucker Meghan, Kornhauser Jon, Ren Jianmin, MacNeill Joan, Gygi Steven P., Druker Brian J., Heinrich Michael C., Rush John, Polakiewicz Roberto D.
Primary Institution: Cell Signaling Technology, Inc.
Hypothesis
The molecular mechanisms by which FLT3 mutations lead to cell transformation in acute myeloid leukemia (AML) remain unclear.
Conclusion
This study provides a valuable resource for investigating oncogenic FLT3 signaling in human leukemia.
Supporting Evidence
- FLT3 mutations are found in approximately 30% of patients with acute myeloid leukemia (AML).
- Over 1000 tyrosine phosphorylation sites were identified from about 750 proteins in leukemia cell lines.
- Phosphoproteomic analysis extended to primary AML patient samples identified over 200 tyrosine and 800 serine/threonine phosphorylation sites.
Takeaway
Researchers looked at how a specific protein called FLT3 behaves in leukemia cells to understand how it might cause cancer.
Methodology
Phosphoproteomic analysis of FLT3 signaling in human leukemia cells using mass spectrometry.
Limitations
The study may not capture all phosphorylation events due to the time required for sample collection.
Participant Demographics
Included 8 human AML cell lines and 3 human B-ALL cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website